-Ischemia-reperfusion induces both necrotic and apoptotic cell death. The ability of adenosine to attenuate reperfusioninduced injury (RI) and the role played by adenosine receptors are unclear. We therefore studied the role of the A 3 receptor (A3R) in ameliorating RI using the specific A3R
sion. Indeed, pretreatment with a drug before ischemia is seldom possible in the setting of acute myocardial infarction because it is not always possible to define that particular category of patients at risk until it is too late (48) .
Reperfusion of ischemic myocardium is necessary for tissue salvage but can paradoxically cause lethal reperfusion injury and hence cell death (49) . A large component of cell death during myocardial ischemia-reperfusion results from cellular necrosis. Furthermore, recent evidence suggests that programmed cell death (apoptosis) contributes in part to overall myocyte cell death during the reperfusion period (6, 10) . It has been proposed that the apoptotic program is initiated shortly after the onset of ischemia, but there is evidence that the process is amplified during reperfusion (6, 10, 29) .
Therefore, there is a defined target in which pharmacological therapy can be designed to protect the myocardium against both the necrosis and apoptosis that occur as a consequence of reperfusion.
Studies investigating the effects of exogenous adenosine itself as well as adenosine A 1 and A 2a receptor agonists when administered at reperfusion have yielded conflicting results (9, 11, (23) (24) (25) 42) . However, there are very little data investigating the effects of adenosine A 3 receptor activation on reperfusion injury, although Vinten-Johansen and colleagues (14) have shown that A 3 receptor activation at reperfusion attenuated neutrophil-mediated reperfusion injury in the dog. Notably, however, activation of adenosine A 3 receptors has been shown to reduce the degree of apoptosis in models of ischemia-reperfusion in the brain (1) and in HL-60 leukemia and U-937 lymphoma cell lines (47) .
The objective of this study was therefore to determine whether activation of adenosine A 3 receptors using the specific adenosine A 3 agonist 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxi-N-methyl-b-Dribofuranuronamide (2-Cl-IB-MECA) could protect the isolated perfused rat heart against cell death when given at the moment of reperfusion.
Additional experiments were performed to rule out the possibility of a nonspecific activation of the adenosine A 2a receptor that may contribute to the observed protection. For this purpose, we administered concomitantly the adenosine A 3 receptor agonist 2-Cl-IB-MECA and the A 2a receptor antagonist 8-3 chlorostyryl caffeine (CSC) during reperfusion. Also, we investigated the role of a specific A 2a agonist, CGS-21680, given at reperfusion.
Furthermore, we investigated the effects of adenosine A 3 receptor activation at reoxygenation on apoptotic and necrotic cell injury using an isolated rat myocyte model of simulated ischemia/reoxygenation.
MATERIALS AND METHODS

Drugs
A highly specific adenosine A3 receptor agonist, 2-Cl-IB-MECA, and an adenosine A2a receptor agonist, CGS-21680, were purchased from Tocris. 3-Ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5 dicarboxylate (MRS-1191), a specific blocker of the adenosine A 3 receptor, and the adenosine A2a receptor antagonist CSC were purchased from Sigma. Drugs were selected for their high specificity for the rat tissue (4, 23) . The drugs were dissolved in DMSO, and the aliquots were frozen at Ϫ20°C.
Ex Vivo Rat Hearts
Animals. Male Sprague-Dawley rats (350-400 g body wt) were used. All animals were obtained from the same source, fed a standard diet, housed under the same conditions, and received humane care in accordance with The Guidance on the Operation of the Animals (Scientific Procedures) Act of 1986. During the experiments, there were seven exclusions, these being due to technical problems (i.e., hearts not properly stabilized).
Heart preparation. The animals were anesthetized by an intraperitoneal administration of pentobarbital sodium (55 mg/kg) and anticoagulated with heparin (300 units). The hearts were excised, placed in ice-cold buffer, and within 1 min mounted in a constant-pressure Langendorff system (80 mmHg). They were perfused retrogradely with a modified Krebs-Henseleit (KH) bicarbonate buffer containing (in mM) 118.5 NaCl, 25 NaHCO 3, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.7 CaCl2, and 12 glucose. All solutions were gassed with 95% O2-5% CO2 (pH 7.4) and maintained at 37°C. The temperature was permanently monitored by a thermocouple inserted in the right ventricle. A latex isovolumic balloon was introduced in the left ventricle through an insertion performed in the left atrial appendage and inflated up to 5-10 mmHg. Functional monitoring was performed via a pressure transducer connected to a LabSystem chart recorder. Left ventricular developed pressure, heart rate, and coronary flow were registered at regular intervals. To induce ischemia, a surgical needle was inserted under the left main coronary artery and the ends of the thread were passed through a small plastic tube to form a snare. Tightening the snare induced regional ischemia and releasing the ends of the thread allowed reperfusion to commence. At the end of reperfusion, the snare was tightened to reocclude the coronary artery branch. A saline solution of 0.12% Evans blue was infused slowly via the aorta to delineate the nonischemic zone of the myocardium, which stained dark blue. The hearts were frozen, sliced into 1-mm-thick transverse sections, and incubated in triphenyltetrazolium chloride solution (1% in phosphate buffer, pH 7.4) at 37°C for 10-12 min. They were then fixed in 10% formalin for at least 4 h. Viable tissue stained red and infarcted tissue appeared pale. The risk zone and infarct areas were traced onto acetate sheets. With the use of computerized planimetry (Summa Sketch II, Summagraphics), the percentage of infarcted tissue within the volume of the myocardium at risk was calculated (I/R%).
Experimental groups. All hearts were allowed to stabilize for 15 min before being subjected to 35 min of regional ischemia followed by 120 min of reperfusion. One minute before reperfusion, they were randomly distributed into the following groups: 1) hearts perfused with normal buffer (controls, n ϭ 11); 2) hearts perfused with different concentrations of the adenosine A 3 receptor agonist 2-Cl-IB-MECA (100, 30, 10, 1 or 0.1 nM, n ϭ 4, 4, 6, 8, and 4, respectively) added in the buffer throughout the reperfusion period; 3) hearts perfused for the same duration with a mixture of 1 nM 2-Cl-IB-MECA and 1 M MRS-1191, a specific A 3 antagonist (n ϭ 6); or 4) perfused only with the antagonist added in the buffer (n ϭ 4). There were also hearts that underwent the same protocol in the presence of 1 nM A 3 agonist and 1 M CSC (A 2a antagonist, n ϭ 5) or 100 nM A2a agonist (CGS-21680, n ϭ 5) during reperfusion.
Rat Cardiomyocytes
Cardiomyocytes preparation. Rat ventricular myocytes were isolated by conventional enzymatic dissociation. In brief, male Sprague-Dawley rats (350-400 g body wt) were anesthetized with pentobarbital sodium (55 mg/kg) and anticoagulated with heparin (300 units) intraperitoneally. The hearts were quickly excised, mounted on a Langendorff apparatus, and perfused with modified ADS control buffer containing (in mM) 137 NaCl, 3.8 KCl, 0.49 MgCl2, 4 HEPES, 10 glucose, and 10 2,3-butanedione monoxime (pH 7.4). The perfusate was bubbled with 95% O2-5% CO2 and maintained at 37°C. After 5 min, the hearts were switched to a modified Tyrode solution containing 1.0 mg/ml collagenase (Worthington type II) and 50 M calcium for 10-15 min. They were then perfused for 5 min with ADS buffer containing 50 M calcium alone. The hearts were removed from the perfusion apparatus, and the atria were trimmed away. The ventricles were minced and incubated in a shaking bath for 5 min in collagenasecontaining solution. Cells were then filtered through nylon mesh and washed with restoration buffer [containing (in mM) 137 NaCl, 3.8 KCl, 0.49 MgCl2, 4 HEPES, 10 glucose, 10 2,3-butanedione monoxime, 2 carnitine, 5 creatine, 5 taurine, and 5 Na-pyruvate (pH 7.4)]. The calcium concentration was gradually brought back to 1.25 mM.
Experimental protocol. The cardiac myocytes were exposed to lethal simulated ischemia as follows: the normal restoration medium was replaced with 2 ml Esumi ischemic buffer (5) [containing (in mM) 137 NaCl, 12 KCl, 0.49 MgCl2, 0.9 CaCl2 ⅐ H2O, 4 HEPES, 20 Na-lactate, 10 deoxyglucose, and 10 KCN (pH 6.5)], and the cells were incubated at 37°C for 45 min in the hypoxic chamber in an atmosphere of 0% O2-5% CO2 balanced with argon (BOC gases). For control conditions with or without drug treatments, myocytes were cultured with 2 ml modified Esumi control buffer for 2.75 h at 37°C in an atmosphere of 21% O2-5% CO2 balanced with N2 (normoxic environment). To investigate whether 2-Cl-IB-MECA (adenosine A3 agonist) protected adult cardiac myocytes from reoxygenation injury, the cells were incubated with different concentrations of 2-Cl-IB-MECA (0.1, 1, 10, 30, and 100 nM) for 2 h at the point of reoxygenation and in the presence and absence of the selective adenosine A3 receptor antagonist MRS-1191 (1 M).
Assessment of apoptosis and necrosis. The cells were washed with 1 ml of cold PBS (pH 7.4; 140 mM NaCl, 5 mM KCl, and 1.8 mM CaCl 2). They were then incubated for 10 min in the dark at room temperature in annexin V-FITC solution (1:50 in annexin binding buffer). Propidium iodide (PI; 100 mg/ml) was added to the myocytes loaded with annexin V. Samples were analyzed immediately by flow cytometry using a Partec flow cytometer (Partec; Mü nster, Germany) equipped with a 488-nm argon laser, with settings optimized for detection of fluorescein and PI. Annexin V has been shown previously to detect the early stages of apoptosis by binding to the phosphatidyl serine (PS) residues, which are translocated on the external face of the cell membrane (2, 38, 40) . Translocation of PS occurs early in apoptosis while the cell membrane is still intact. Cellular necrosis was determined using PI. The assay is based on the vital binding of PI to the nuclei of cells whose plasma membranes have become permeable due to cell damage (7) . Results are expressed as the percent annexin V-positive/PI-negative (early apoptotic) and annexin-positive/PI-positive (necrotic) total numbers of cells.
Statistical Analysis
Data, expressed as means Ϯ SE, were compared using one-way ANOVA and Fisher's protected least-significantdifference test for multiple comparisons. The differences between groups were considered significant when P Ͻ 0.05.
RESULTS
Role of Adenosine A 3 Receptor Activation at Reperfusion Upon Infarction in Isolated Perfused Rat Heart
Homogeneity among experimental groups. The results of 45 successful experiments were included. The risk zone was not significantly different between groups (0.57-0.64 cm 3 ). Heart rate, coronary flow, and left ventricular developed pressure were not significantly different among groups at the end of the stabilization period (data not presented).
Protective effect of adenosine A 3 agonist 2-Cl-IB-MECA is dose dependent. Our data showed that, in the isolated perfused rat hearts, there is a dose-dependent effect of the adenosine A 3 agonist 2-Cl-IB-MECA related to its ability to limit infarct size. Infarct developed in the risk zone (I/R%) was not different from control hearts when the agonist was present at concentrations of 30 nM or higher I/R% (44.2 Ϯ 2.7 in control vs. 41.2 Ϯ 5.6 at 100 nM and 40.2 Ϯ 6 at 30 nM, P Ͼ 0.05). However, lower concentrations of 2-Cl-IB-MECA significantly reduced the development of infarction I/R% (33.6 Ϯ 4 at 10 nM and 21.9 Ϯ 2.4 at 1 nM, P Ͻ 0.05 vs. control). The protective effect started to diminish when the agonist was further diluted I/R% (35.8 Ϯ 3.3 at 0.1 nM) (Fig. 1) .
Protective effect of 2-Cl-IB-MECA is due to a specific effect upon A 3 receptors. To elude the possibility that the protective effect we observed could have been caused by a nonspecific activation of other adenosine receptors, we used 2-Cl-IB-MECA, which has been previously shown to be a highly specific agonist of the adenosine A 3 receptor (4, 23) . However, at high doses, this drug was observed to have marked vasodilatator effects, increasing the coronary flow (Fig. 2) , possibly due to some adenosine A 2 receptor activation. Furthermore, this effect was not accompanied by any protection (Fig. 1 ). There were no differences in heart rate among the groups, which can be an indicator that 2-Cl-IB-MECA has no major effect upon adenosine A 1 receptors at any concentration (data not shown).
In addition to that, the reduction in infarct size obtained with 1 nM 2-Cl-IB-MECA was completely abolished in the presence of 1 M MRS-1191, a specific A 3 antagonist for the rat tissues (I/R%: 44.2 Ϯ 2.7 in controls vs. 21.9 Ϯ 2.4 in 2-CL-IB-MECA, P Ͻ 0.05, and vs. 40.7 Ϯ 3.9 in 2-Cl-IB-MECA ϩ MRS-1191, P Ͼ 0.05; Fig. 3 ). The antagonist alone did not modify the I/R% significantly compared with control hearts. 
Role of Adenosine A 3 Receptor Activation at Reoxygenation Upon Rat Adult Ventricular Myocyte Survival
Exposing the adult rat cardiac myocytes to 45 min of hypoxia followed by 120 min of reoxygenation induced significant injury, resulting in 17.1 Ϯ 1.3% apoptotic cells and 23.1 Ϯ 1.5% necrotic cells as measured using annexin-V-fluorescein and PI labeling, which detect early apoptotic and necrotic cells, respectively. To assess the role of adenosine A 3 receptor activation in reducing myocyte injury during reoxygenation, we used the specific agonist 2-Cl-IB-MECA. The cardioprotective ability of the A 3 agonist was observed at 1 nM, significantly decreasing the percentage of both apoptotic (5.7 Ϯ 2.6% in 1 nM 2-Cl-IB-MECA vs. 17.1% Ϯ 1.3 in control) and necrotic cells (13.7 Ϯ 2.0% in 1 nM 2-CL-IB-MECA vs. 23.1 Ϯ 1.5% in control). At higher concentrations of 2-Cl-IB-MECA (Ͼ30 nM) and the lowest concentration (0.1 nM), there was no protection observed (Fig. 5A) .
To determine whether the protection afforded by the adenosine A 3 agonist is mediated by the A 3 receptor, a selective antagonist of this receptor was used. The A 3 antagonist MRS-1191 blocked the 2-Cl-IB-MECA-elicited cardioprotection in myocytes, increasing both necrosis (25.0 Ϯ 1.7%) and apoptosis (17.1 Ϯ 1.2%) at values not significantly different from the respective controls (23.1 Ϯ 1.3% and 17.6 Ϯ 2.2%, respectively; Fig. 5B ).
DISCUSSION
The major finding of the current study demonstrated that the activation of adenosine A 3 receptors via administration of the specific adenosine A 3 agonist 2-Cl-IB-MECA at reperfusion not only significantly reduced infarct size in the isolated perfused rat heart after ischemia but also exerted an antiapoptotic and antinecrotic effect in the isolated adult rat myocyte. Previous investigators have shown, in a variety of models, that preconditioning the heart via activation of adenosine receptors can protect against ischemia-reperfusion injury (19, 24, 36, 42) . With regard to reperfusion injury, however, activation of adenosine A 3 receptors has only been shown to attenuate neutrophil-mediated reperfusion injury (14) , and no measures of infarct reduction or cell death have ever been reported. To our knowledge, this is the first study to identify a protective role for the adenosine A 3 receptor in the heart when activated at reperfusion using infarct size as the end point of injury.
Our data are in agreement with those of Lubitz et al. (45) , who demonstrated that treatment with the A 3 agonist 2-Cl-IB-MECA after induced cerebral ischemia resulted in improved neuronal preservation, decreased intensity of reactive gliosis, and pronounced reduction of microglial infiltration. Furthermore, they also demonstrated a reduction of infarction in the brain after adenosine A 3 receptor activation.
We observed a dose-dependent effect of the adenosine A 3 receptor agonist on its ability to limit infarct size in the isolated perfused rat heart. At high doses of 100 and 30 nM, no protection was observed. However, we saw a significant reduction in myocardial infarction at 10 and 1 nM, respectively. At further dilution, this protection was not sustained. Therefore, it appears that the optimal dose for protection against reperfusion injury in this model using this A 3 agonist is 1 nM. Our study using 2-Cl-IB-MECA showed similar profiles when apoptosis and necrosis were evaluated in rat cardiomyocytes as separate end points of injury. Indeed, the adenosine A 3 receptor has been reported to mediate both cell protection and cell death simply depending on the degree of receptor activation and/or specific pathophysiological conditions. A mild subthreshold activation of the adenosine A 3 receptor has been shown to decrease apoptotic injury induced by either chemical toxicity or ischemia (1, 8, 32, 44, 47) . In contrast, at high concentrations (Ͼ10 M), 2-Cl-IB-MECA can trigger cell death by either necrosis or apoptosis (1, 31, 33) .
Our results confirm those of Lasley et al. (20) , who showed in isolated rat hearts that at Ն30 nM 2-Cl-IB-MECA caused an increase in vasodilatation that was attenuated by Sch-58261 (adenosine A 2a receptor antagonist). In our study, protection was observed by 2-Cl-IB-MECA only at concentrations of 1 and 10 nM, which did not cause vasodilation, indicating no role for an A 2a receptor-mediated vasodilation being involved in the 2-Cl-IB-MECA-induced protection.
However, some authors have previously demonstrated that the activation of the adenosine A 2a receptor may be protective (15, 19) with respect to its inhibitory action upon the neutrophil-related processes (15) .
To clarify the possible involvement of the A 2a receptor in the protection observed in our model, we investigated the effect of a concomitant administration, at reperfusion, of an A 3 agonist (2 Cl-IB-MECA) and an A 2a antagonist (CSC) as well as the direct effect of A 2a receptor stimulation at reperfusion using CGS-21680. The data we obtained showed that the A 2a receptor antagonist appears to block the protective effect of the A 3 agonist. However, the direct activation of the adenosine A 2a receptor at reperfusion does not confer protection in terms of infarct reduction in our model.
Our explanation for these contradictory results is based on studies showing that an increased stimulation of the A 3 receptor is in itself proapoptotic (Figs. 1 and 5A) (12, 45) . We believe that this increased stimulation takes place when the A 3 agonist, in a protective dose, is coadministered with the A 2a antagonist. The blockage of the A 2a adenosine receptor may allow for more adenosine, occurring naturally in ischemia, to interact with the A 3 receptor. As a result, an indirect increased stimulation of the A 3 receptor will take place, with its consequence being an increase in cell death. Of importance is the fact that the addition of an A 2a agonist failed to demonstrate any protection, which highlights the potential problems with the A 2a antagonist.
Furthermore, it has been shown that adenosine A 3 receptors are expressed in resident inflammatory cells such as mast cells (28, 37) , where they can stimulate the release of stored mediators including histamine, cytokines, and proteolytic enzymes as well as numerous other proinflammatory mediators. It could be argued, therefore, that at higher concentrations of 2-Cl-IB-MECA, adenosine A 3 receptors may increase infarct size by potentiating the inflammatory response and hence reduce any beneficial effects observed through activation of A 3 receptors via separate signaling path- ways. We believe this can be discounted in our study as the same concentration-related protection via adenosine A 3 receptors was observed in the mast cell-free system of the isolated rat myocyte.
Our data suggest that a significant component of the cell survival effect of 2-Cl-IB-MECA was in attenuating apoptosis. This was illustrated by the fact that at a concentration of 10 nM, a significant reduction in the apoptotic component of cell death was observed in the myocyte model, whereas, in the whole heart, although a significant reduction in infarct was seen at this dose, this did not produce maximum infarct size reduction.
The specificity of 2-Cl-IB-MECA to induce adenosine A 3 receptor-mediated protection was confirmed using the specific antagonist MRS-1191, which is well documented to be highly specific for rat adenosine A 3 receptors (4, 26) . This antagonist has also been shown to have no effect on A 2a receptor-mediated dilation of cerebral arterioles, again confirming its specificity for adenosine A 3 receptors (22) . We demonstrated that MRS-1191 completely abolished the protection conferred by 1 nM 2-Cl-IB-MECA when given at reperfusion in the isolated rat heart. Furthermore, this abrogation of protection was also observed in the isolated rat myocyte against both apoptosis and necrosis.
The mechanism involved in the A 3 receptor-mediated effects on anti/proapoptotic pathways remains to be elucidated. Adenosine A 3 receptors were demonstrated to specifically stimulate phosphorylation of the serine/threonine kinase Akt. The activation of Akt has been shown to inhibit programmed cell death (3, 16, 35) . In cells exposed to UV light, adenosine A 3 receptor activation has been shown to reduce apoptosis via the Akt pathway (8) . It is therefore feasible that the protection observed in our study could be acting through this signaling pathway. It has also been proposed that stimulation of adenosine A 3 receptors results in the phosphorylation of ERK1/2 (30) . It is therefore conceivable that the protection induced by the adenosine A 3 receptors maybe due to the triggering of specific reperfusion injury salvage kinases (48) .
In summary, we demonstrated that activation of adenosine A 3 receptors using the specific adenosine A 3 receptor agonist 2-Cl-IB-MECA can protect the isolated perfused rat heart when given at the onset of reperfusion. Furthermore, the apoptotic component of cell death, which contributes to myocardial infarction, was also ameliorated by adenosine A 3 receptor activation.
Further investigation into the role of adenosine A 3 receptors in lethal reperfusion injury may lead to new therapeutic strategies in the treatment of ischemic heart disease. Compounds activating adenosine A 3 receptors may have the added advantage, as potent therapeutic agents, by being free from the bradycardic and hypotensive side effects characteristic of the other adenosine receptor activation.
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